Article: ROZEREM(TM) (ramelteon) Showed Significant Reduction in Time to Fall Asleep With No Evidence of Rebound Insomnia or Withdrawal Effects.

Rozerem.(NEW PRODUCTS THIS QUARTER)(Brief Article)
MPR Monthly Prescribing Reference;  November 1, 2005 ;     700+ words ... ... to placebo. Studies indicated that there was no evidence of next-day residual effect (after 2 nights of dosing) or rebound insomnia. Ramelteon is capable of reducing testosterone and cortisol levels and increasing prolactin levels. If unexplained amenorrhea ...

Rozerem.(Hypnotic from Takeda Chemical Industries Ltd for ...
Physician Assistants' Prescribing Reference;  December 22, 2005 ;     700+ words ... ... to placebo. Studies indicated that there was no evidence of next-day residual effect (after 2 nights of dosing) or rebound insomnia. Ramelteon is capable of reducing testosterone and cortisol levels and increasing prolactin levels. If unexplained amenorrhea ...

Article: Study Demonstrated ROZEREM(TM) (ramelteon) Does Not Affect ...
PR Newswire;  June 13, 2007 ;     700+ words ... ... studies presented today demonstrated that ROZEREM did not affect body sway at peak plasma ... data are important because they show that ROZEREM may be a safe sleep medication for the ... patients' memories were not affected by ROZEREM the next morning," said Gary Zammit ...

Article: Ads may jolt pill sales: The FDA approved Takeda Pharmaceuticals' ...
Chicago Tribune (Chicago, IL);  July 16, 2006 ;     700+ words ... ... consumers for its new sleeping pill, Rozerem, which the Food and Drug Administration ... other prescription sleeping aids pose. Rozerem will compete against drugs like Ambien ... about $100 million to launch an array of Rozerem ads, but the company would not confirm ...

Article: AbelsonTaylor Wins 57 Honors in Major Ad Competitions, Claiming ...
PR Newswire;  May 14, 2007 ;     700+ words ... ... campaign materials supporting the sleep drug Rozerem. The 26-year-old agency won a Global Award for Rozerem in the category of exhibit booth design ... World Wide Web (WWW) Health Award for the Rozerem Web site, and two DTC National Advertising ...

Article: Takeda sees new Rozerem tact pay off.(DTC REPORT)(Takeda ...
Medical Marketing & Media;  September 1, 2007 ;     700+ words ... ... campaign for Takeda's insomnia drug Rozerem has generated lots of buzz, but not the ... evolving the campaign to drive trials of Rozerem. The company says two new TV spots that ... prompted more patients to actually mention Rozerem by name when discussing treatment options ...

Article: Unfavorable Tier Placement Makes Safer Insomnia Drug, Takeda's ...
PR Newswire;  October 16, 2006 ;     700+ words ...HMOs' Tier Assignment of Rozerem and Lunesta Ensures Ambien's Status ... benign safety profile, Takeda's Rozerem (ramelteon), the first unscheduled ... percentage of primary care physicians select Rozerem as a first-line agent for primary ...